Drug Research
Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition
Cryoport, Inc., a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, announced the acquisition of Tec4med Lifescience GmbH, a...
Drug Research
Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurmas portfolio companies
Samsung Biologics to provide de-risking, development, manufacturing services, and seamless transitions for biologics from early stages of development to large-scale commercialization
The partnership will streamline gene to IND process to accelerate lead candidate selection and advance CMC along clinical development
Multi-year...
Drug Research
Andelyn Biosciences and Purespring Therapeutics Partner to Manufacture Novel Gene Therapies for Kidney Diseases
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Purespring Therapeutics, a biotech innovator company, to accelerate the manufacture of their gene therapies for the treatment of chronic...
Drug Research
Roche – Biogen Settle US Patent Law Suit For Arthritis Drug
Based on a filing on October 23 in Massachusetts federal court, Roche, the Swiss pharmaceutical giant, has reached a settlement in a patent lawsuit against Biogen, which happens to be a U.S. biotech firm. The lawsuit was concerning Biogen's...
BioPharma
CDMO-Biotech Collab Diminish Business Risk In Drug Creation
Biotech companies go on to face numerous challenges, particularly while in the clinical phase of drug development, in today's fast-paced industry. The astronomically high costs, complicated manufacturing processes, as well as regulatory hurdles related to biologics can go on...
Drug Research
Vetter Further Invests €230M in New Production Building
Vetter, a global CDMO, is making additional investments as part of its long-lead goals for continued expansion and to support customer needs. The company is investing €230 million in its new production building, which is currently under construction at its...
Drug Research
Lonza to enhance commercial antibody-drug conjugate supply capacity
Lonza is planning to build a commercial-scale aseptic current good manufacturing practice (cGMP) filling line at its site in Stein, Switzerland. The new filling line will facilitate the aseptic filling of highly-potent antibody drug conjugates (ADCs) and lyophilisation under...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















